These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Roldán V; Marín F Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516 [No Abstract] [Full Text] [Related]
24. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. Husted SE; Nielsen HK Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961 [TBL] [Abstract][Full Text] [Related]
25. Assessing non-inferiority: a combination approach. Gao P; Ware JH Stat Med; 2008 Feb; 27(3):392-406. PubMed ID: 17575568 [TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry. Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012 [TBL] [Abstract][Full Text] [Related]
28. The clinical and economic impact of bivalirudin for percutaneous coronary intervention. Malik N; Gershlick AH Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):699-706. PubMed ID: 24219045 [TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986 [TBL] [Abstract][Full Text] [Related]
30. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Althunian TA; de Boer A; Klungel OH; Insani WN; Groenwold RH Trials; 2017 Mar; 18(1):107. PubMed ID: 28270184 [TBL] [Abstract][Full Text] [Related]
31. The use of putative placebo in active control trials: two applications in a regulatory setting. Durrleman S; Chaikin P Stat Med; 2003 Mar; 22(6):941-52. PubMed ID: 12627411 [TBL] [Abstract][Full Text] [Related]
32. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. Cohen M; Hoekstra J; Giugliano R; Granger CB; Gurbel PA; Hollander JE; Manoukian SV; Pollack CV; Saucedo JF J Interv Cardiol; 2008 Aug; 21(4):283-99. PubMed ID: 18754964 [TBL] [Abstract][Full Text] [Related]
33. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. Husted SE; Nielsen HK Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659 [TBL] [Abstract][Full Text] [Related]
35. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Gamalo MA; Tiwari RC; LaVange LM Pharm Stat; 2014; 13(1):25-40. PubMed ID: 23913880 [TBL] [Abstract][Full Text] [Related]
36. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Jennings LK; Saucedo JF Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712 [TBL] [Abstract][Full Text] [Related]
37. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis. Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109 [TBL] [Abstract][Full Text] [Related]
38. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW; JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378 [TBL] [Abstract][Full Text] [Related]
39. A ratio test in active control non-inferiority trials with a time-to-event endpoint. Wang YC; Chen G; Chi GY J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. Singh S; Molnar J; Arora R J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):283-91. PubMed ID: 18172222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]